Braveheart Bio (NASDAQ:BRVE) Issues Quarterly Earnings Results

Braveheart Bio (NASDAQ:BRVE) announced its quarterly earnings results on Tuesday. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.40, Zacks reports.

Braveheart Bio Trading Up 0.8%

BRVE stock traded up $0.16 during mid-day trading on Tuesday, reaching $19.62. 211,467 shares of the company’s stock were exchanged, compared to its average volume of 453,476. Braveheart Bio has a 12-month low of $16.70 and a 12-month high of $32.00. The firm has a 50 day moving average of $22.56. The firm has a market capitalization of $1.77 billion and a P/E ratio of -7.82.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $40.00 price objective on shares of Braveheart Bio in a report on Tuesday, October 20th. Wall Street Zen raised Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. Stifel Nicolaus initiated coverage on shares of Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $45.00 price target on the stock. The Goldman Sachs Group started coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $48.00 price target on the stock. Finally, Jefferies Financial Group started coverage on shares of Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating and a $48.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $45.25.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.